Key clinical point: Preoperative chemoradiotherapy did not improve overall survival among patients with resectable or borderline resectable pancreatic cancer.
Major finding: The median overall survival was 16.0 months in the preoperative chemoradiotherapy arm and 14.3 months in the immediate surgery arm (hazard ratio, 0.78; P = .096).
Study details: PREOPANC was a phase 3 trial of 246 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.
Disclosures: The Dutch Cancer Society funded the study. The authors disclosed financial affiliations with Bristol-Myers Squibb, Eisai, Ipsen, Merck Serono, and other companies.
Versteijne E et al. J Clin Oncol. 2020 Feb 27. doi: 10.1200/JCO.19.02274.